What is the QCSI score?

The QCSI (Quick COVID Severity Index) is a 3-variable bedside score developed specifically for COVID-19 patients presenting to the emergency department. It uses supplemental oxygen requirement, respiratory rate, and room-air SpO2 to estimate 24-hour critical respiratory illness risk. Scores range from 0 to 13.

How is the QCSI calculated?

QCSI scoring: O2 requirement (none=0, 1–2 L=1, 3–4 L=2, 5–6 L=3, 7–9 L=4, ≥10 L=5); RR ≤22=0, 23–28=1, ≥29=3; SpO2 on room air ≥97%=0, 95–96%=1, 93–94%=2, ≤92%=5. Total range 0–13.

How is QCSI interpreted for COVID-19 severity?

QCSI 0–3: low risk — 1.4% ICU admission rate. QCSI 4–6: moderate risk — 11.7% ICU admission rate. QCSI 7–13: high risk — 46.4% ICU admission rate. These thresholds guide ED disposition decisions from discharge with monitoring to direct ICU admission.

What is the ICU admission rate for high QCSI scores?

In the derivation and validation cohort of 1,060 COVID-19 ED patients, QCSI 7–13 was associated with a 46.4% ICU admission rate within 24 hours. This is among the highest-risk thresholds of any published COVID-19 severity score at ED presentation, and warrants immediate escalation consideration.

How does QCSI compare to NEWS2 for COVID-19?

QCSI was specifically derived for COVID-19 and outperformed NEWS2, qSOFA, and CURB-65 in the original validation study (C-statistic 0.85). NEWS2 was adapted for COVID-19 from a general early warning score and was not specifically trained on COVID-19 outcomes. QCSI's disease-specific derivation gives it an advantage in this specific population.

What are the COVID-19 discharge criteria from the ED?

Safe ED discharge for COVID-19 generally requires: QCSI 0–3 OR maintaining SpO2 ≥94% on minimal or no supplemental O2, no rapidly progressive symptoms, reliable access to follow-up, ability to monitor symptoms at home, and no high-risk features (age >65, obesity, immunosuppression, multiple comorbidities) that would override a low QCSI score.

Why is SpO2 on room air so heavily weighted in QCSI?

SpO2 ≤92% on room air carries 5 points — the maximum for any individual score item — because severe hypoxemia at rest is the most critical indicator of impending respiratory failure in COVID-19. COVID-19 pneumonia characteristically causes 'silent hypoxemia' where patients may not feel dyspneic despite severely reduced SpO2, making objective measurement essential.

Can QCSI predict mortality in COVID-19?

QCSI was primarily validated for ICU admission (a proxy for critical illness), not directly for mortality. However, ICU admission is strongly associated with mortality in COVID-19, and high QCSI scores correlate with both. For mortality prediction, clinical severity scoring tools and inflammatory marker panels (CRP, D-dimer, ferritin, IL-6) provide complementary prognostic information.

What is oxygen requirement scoring in QCSI?

QCSI scores O2 flow rate in steps: no supplemental O2 = 0 points; 1–2 L/min = 1 point; 3–4 L/min = 2 points; 5–6 L/min = 3 points; 7–9 L/min = 4 points; ≥10 L/min = 5 points. This graduated scoring captures the continuum from mild to severe hypoxemia requiring high-flow oxygen delivery.

Should QCSI replace clinical judgment in COVID-19 triage?

No. QCSI is a decision-support tool, not a replacement for clinical judgment. Patient age, comorbidities, social support, symptom trajectory, inflammatory markers, and overall clinical appearance must all be integrated with the QCSI score. A low QCSI in an elderly immunocompromised patient with rapidly worsening symptoms should still prompt admission consideration.

What COVID-19 SpO2 level requires hospital admission?

Most clinical guidelines recommend hospital admission for COVID-19 patients with SpO2 below 94% at rest or below 90% with minimal exertion (6-minute walk test). SpO2 ≤92% on room air scores 5 points in QCSI, almost certainly placing the patient in moderate-to-high risk range requiring hospitalization.

Who developed the QCSI score?

QCSI was developed by Valle et al. at Yale New Haven Hospital and published in Annals of Emergency Medicine in 2021. It was derived from 1,060 COVID-19 patients across two academic emergency departments and prospectively validated in an independent cohort. The C-statistic for ICU admission was 0.85.

Online Medical Tools — qCSI Score

Printed on 9/2/2026

For informational purposes only. This is not medical advice.

Emergency

qCSI Score

The Quick COVID Severity Index (qCSI) is a bedside score designed to estimate near-term respiratory decompensation risk in adults with respiratory infection syndromes. It uses three immediately available variables: respiratory rate, pulse oximetry, and nasal cannula oxygen flow rate.

Formula: qCSI = respiratory rate points + SpO2 points + oxygen flow points (0-13).

Respiratory Rate

/min

Pulse Oximetry (SpO2)

Nasal Cannula Oxygen Flow

L/min

Save your results with a free account

Keep a history of calculations, favorite tools, and access your dashboard anytime.

Create free account Sign in

How It Works

Assess the 3 variables at ED or hospital presentation

Measure three bedside respiratory variables: (1) supplemental oxygen requirement via nasal cannula (0–10+ L/min, or none); (2) respiratory rate per minute; (3) SpO2 on room air (measured without supplemental oxygen). Ensure SpO2 is obtained on room air — values measured on supplemental O2 will underestimate severity.

Apply the scoring thresholds

Score each variable: O2 requirement (none=0, 1–2 L/min=1, 3–4 L/min=2, 5–6 L/min=3, 7–9 L/min=4, ≥10 L/min=5); RR (≤22/min=0, 23–28=1, ≥29=3); SpO2 on room air (≥97%=0, 95–96%=1, 93–94%=2, ≤92%=5). Sum all points for total qCSI (0–13).

Interpret risk category and guide disposition

Low risk (0–3): 1.4% ICU admission rate — consider discharge with close monitoring. Moderate risk (4–6): 11.7% ICU admission. High risk (7–13): 46.4% ICU admission — strongly consider hospitalization or ICU-level care. Combine with clinical factors including age, comorbidities, and inflammatory markers for optimal disposition decisions.

Who Uses the qCSI Score

COVID-19 ED Triage and Disposition

Emergency physicians

QCSI was specifically derived and validated in COVID-19 patients presenting to the ED. Use it at initial evaluation to stratify ICU admission risk and guide admission vs. discharge decisions during COVID-19 surges or for patients with COVID-related hypoxemic respiratory failure.

Risk Stratification for Admission vs. Discharge

Emergency physicians, hospitalists

QCSI low-risk threshold (0–3) identifies patients with only 1.4% ICU admission risk — suitable candidates for discharge with close outpatient monitoring, telehealth follow-up, and pulse oximetry at home. High-risk threshold (7+) predicts 46.4% ICU admission and supports immediate escalation planning.

ICU Bed Planning During Pandemic Surges

Hospital administrators, critical care teams

During COVID-19 surges with limited ICU capacity, QCSI provides an objective respiratory severity triage to allocate high-acuity resources to the highest-risk patients while safely streaming lower-risk patients to step-down or observation units.

Clinical Decision Support for COVID-19 Resource Allocation

Hospital systems, care coordinators

QCSI offers a simple 3-variable score that can be rapidly computed by nurses or respiratory therapists at triage, enabling early identification of high-risk patients before full physician assessment and facilitating timely escalation and resource preparation.

Post-ED Follow-Up Risk Stratification

Primary care, telehealth providers

For patients discharged from the ED with COVID-19 or viral pneumonia, QCSI calculated at discharge provides a quantified risk estimate to guide follow-up intensity — daily SpO2 monitoring, return precautions, and telehealth check-ins for higher-scoring patients.

Pro Tips

SpO2 must be measured on room air — not on supplemental O2

The SpO2 component of QCSI requires assessment off supplemental oxygen. A patient on 4 L/min nasal cannula achieving SpO2 95% may actually be 88% on room air — a critical difference that would jump from 1 point to 5 points in the scoring system. Always document room-air SpO2 separately from the oxygen flow requirement component.

O2 requirement is the most heavily weighted variable (max 5 points)

The oxygen flow rate variable contributes up to 5 of 13 possible points — more than any other single component. A patient requiring ≥10 L/min nasal cannula oxygen immediately scores in the high-risk category based on O2 alone, even with relatively preserved SpO2 and respiratory rate.

QCSI was specifically derived for COVID-19 — not general respiratory illness

Unlike NEWS2 (which was adapted from a general deterioration score), QCSI was derived specifically from COVID-19 patients. Its performance in non-COVID hypoxemic respiratory failure (influenza pneumonia, bacterial pneumonia, ARDS) has not been prospectively validated. Use clinical judgment when applying it outside COVID-19 context.

High-risk (7–13): 46% ICU admission — escalate care immediately

A QCSI score of 7 or higher was associated with 46.4% ICU admission in the derivation cohort. These patients require immediate physician evaluation, early respiratory therapy consultation, preparations for possible escalation to non-invasive ventilation (HFNC or BiPAP), and ICU or step-down admission planning.

Combine QCSI with patient age and comorbidity risk factors

QCSI does not include age, BMI, diabetes, immunosuppression, or cardiovascular disease — all of which independently increase COVID-19 mortality risk. A QCSI of 3 (low) in a 75-year-old with diabetes and heart failure carries far greater risk than the same score in a healthy 35-year-old. Supplement with overall clinical risk assessment.

Monitor COVID-19 inflammatory markers independently of QCSI

CRP, D-dimer, ferritin, LDH, and IL-6 add independent prognostic value beyond QCSI for predicting COVID-19 deterioration and hyperinflammatory phase (cytokine storm). Elevated D-dimer (>1 µg/mL) in particular is associated with thrombotic complications and mortality risk beyond what QCSI captures.

COVID-19 treatment is severity-tiered — QCSI guides the tier

Outpatient high-risk (QCSI 0–3 but high-risk comorbidities): nirmatrelvir/ritonavir (Paxlovid) within 5 days of symptom onset. Hospitalized O2-dependent: remdesivir + dexamethasone. ICU/severe: dexamethasone + baricitinib or tocilizumab + therapeutic anticoagulation for elevated D-dimer. QCSI helps stratify which treatment tier is appropriate.

QCSI low risk (0–3) supports discharge with structured return precautions

Patients with QCSI 0–3 and no high-risk comorbidities can typically be discharged safely with clear return precautions: any increase in O2 requirement at home, SpO2 below 94% at rest or below 90% with minimal activity, respiratory rate persistently above 30, or worsening dyspnea. Provide home pulse oximetry if available.

COVID-19 variants may alter the clinical presentation

Omicron and subsequent variants have shown different patterns of respiratory involvement compared to original and Delta variants — lower rates of severe hypoxemia in vaccinated and boosted individuals. QCSI derived from earlier variant cohorts may underestimate or overestimate risk in different variant-prevalence periods. Calibrate against current clinical experience.

Common Questions About Your Results

Briefly discontinue supplemental oxygen for 1–2 minutes and measure SpO2 — most stable patients tolerate this without significant desaturation. If the patient desaturates rapidly to below 90% or becomes symptomatic within seconds of removing O2, do not continue the test — record the O2 requirement as the primary severity indicator and note SpO2 cannot be safely assessed on room air. This is itself a high-risk sign.

QCSI 4–6 corresponds to 11.7% ICU admission risk — a meaningful risk that warrants strong consideration of hospitalization or at minimum extended observation. Key factors supporting admission: O2 requirement ≥2 L/min, age >60, significant comorbidities (diabetes, obesity, immunosuppression, heart failure), social circumstances that preclude close monitoring at home, or inability to reliably monitor SpO2 at home.

Evidence-Based Methodology

QCSI developed by Valle et al. (Ann Emerg Med 2021) from 1060 COVID-19 patients at two academic emergency departments. C-statistic 0.85 for ICU admission. High-risk threshold 7+: ICU admission 46.4%. Low-risk 0-3: ICU admission 1.4%. Prospective validation in independent cohort. Compared favorably to NEWS2, qSOFA, and CURB-65 for COVID-19 severity prediction.

Clinical Content Trust

Last reviewed:: April 21, 2026
Guideline version:: General evidence framework v2026.04
Source set version:: Primary-source set v1

How to Interpret Your Result

Higher qCSI scores indicate greater short-term risk of respiratory deterioration. Lower scores suggest lower immediate risk, while upper bands warrant closer monitoring and escalation readiness.

Use qCSI as risk support rather than a stand-alone disposition rule.

When to Use This Tool

Use qCSI in adults with acute respiratory infection syndromes when triaging decompensation risk based on bedside respiratory variables.

It is useful for rapid reassessment and communication of risk trajectory.

Limitations

qCSI is cohort-derived and not a universal substitute for clinician judgment, imaging, labs, or full organ-failure assessment.

Patients can deteriorate despite low initial scores, so serial reassessment remains mandatory.

For related assessments, see NEWS2 Score, qSOFA Score and P/F Ratio.

Disclaimer: This tool is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about your health.

Sources

Haimovich AD, et al. Development and Validation of the Quick COVID-19 Severity Index: A Prognostic Tool for Early Clinical Decompensation. Ann Emerg Med. 2020;76(4):442-453.

Changelog

April 21, 2026 · trust-baseline
Clinical trust metadata enabled for this tool page with structured review/version fields.

Related Tools